Literature DB >> 23845436

Par(-4)oxysm in breast cancer.

Tripti Shrestha-Bhattarai1, Nikhil Hebbar, Vivek M Rangnekar.   

Abstract

Women suffering from breast cancer often succumb to incurable recurrent disease resulting from therapy-resistant cancer cells. In this issue of Cancer Cell, Alvarez and colleagues identify downregulation of the tumor suppressor Par-4 as the key determinant in apoptosis evasion, which leads to tumor recurrence in breast cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23845436      PMCID： PMC3743248          DOI： 10.1016/j.ccr.2013.06.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

Review 1.  Emerging targeted therapies for breast cancer.

Authors:  Ricardo H Alvarez; Vicente Valero; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

Review 2.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 3.  Mechanisms of apoptosis by the tumor suppressor Par-4.

Authors:  Nikhil Hebbar; Chi Wang; Vivek M Rangnekar
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

4.  Residual risk of breast cancer recurrence 5 years after adjuvant therapy.

Authors:  Abenaa M Brewster; Gabriel N Hortobagyi; Kristine R Broglio; Shu-Wan Kau; Cesar A Santa-Maria; Banu Arun; Aman U Buzdar; Daniel J Booser; Vincente Valero; Melissa Bondy; Francisco J Esteva
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

5.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

6.  Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy.

Authors:  James V Alvarez; Tien-Chi Pan; Jason Ruth; Yi Feng; Alice Zhou; Dhruv Pant; Joshua S Grimley; Thomas J Wandless; Angela Demichele; Lewis A Chodosh
Journal:  Cancer Cell       Date:  2013-06-13       Impact factor: 31.743

7.  Cancer resistance in transgenic mice expressing the SAC module of Par-4.

Authors:  Yanming Zhao; Ravshan Burikhanov; Shirley Qiu; Subodh M Lele; C Darrell Jennings; Subbarao Bondada; Brett Spear; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

Authors:  Alastair M Thompson; Lee B Jordan; Philip Quinlan; Elizabeth Anderson; Anthony Skene; John A Dewar; Colin A Purdie
Journal:  Breast Cancer Res       Date:  2010-11-08       Impact factor: 6.466

9.  Pathways to breast cancer recurrence.

Authors:  Aamir Ahmad
Journal:  ISRN Oncol       Date:  2013-02-28
  9 in total
  1 in total

1.  Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.

Authors:  Ravshan Burikhanov; Vitaliy M Sviripa; Nikhil Hebbar; Wen Zhang; W John Layton; Adel Hamza; Chang-Guo Zhan; David S Watt; Chunming Liu; Vivek M Rangnekar
Journal:  Nat Chem Biol       Date:  2014-09-14       Impact factor: 15.040
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.